Trajan Group Holdings Ltd 2023 AR2
The report highlights Trajan's performance for the fiscal year ended June 30, 2023, marking its twelfth consecutive year of growth. The company achieved record net revenue of $162.2 million, up 50.7% from the previous year, and a normalized EBITDA of $21.1 million. Key developments included the integration of Chromatography Research Supplies (CRS) and the launch of the MonitorYou Healthy Heart Program. On the ESG front, Trajan formalized its ESG framework, focusing on waste reduction, promoting diversity with over 50% female employees, and conducting a modern slavery risk assessment across its supply chain.
Company: Trajan Group Holdings Ltd
Sector: Health Care
Country: Australia
Year: 2023
Type: AR2
Pages: 120
Trajan Group Holdings Ltd
Annual Report
The report highlights Trajan's performance for the fiscal year ended June 30, 2023, marking its twelfth consecutive year of growth. The company achieved record net revenue of $162.2 million, up 50.7% from the previous year, and a normalized EBITDA of $21.1 million. Key developments included the integration of Chromatography Research Supplies (CRS) and the launch of the MonitorYou Healthy Heart Program. On the ESG front, Trajan formalized its ESG framework, focusing on waste reduction, promoting diversity with over 50% female employees, and conducting a modern slavery risk assessment across its supply chain.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees